Genesys Capital
VC Fund
Toronto, Canada
Genesys Capital is a VC fund in Toronto focused on Biotechnology and Health Care. Genesys Capital is focused on building companies in the high-growth sectors of healthcare and biotechnology. Through its expertise and network, Genesys accelerates the development of commercially viable emerging companies that represent promising biotechnology investment opportunities.
- Total investments:
- 35
- Last investment:
- Lead investor:
- 17%
- Fund size:
- $125M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Genesys Capital invests in
Stages Genesys Capital invests in
Countries Genesys Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $1.8M–$21M
- Series B
- $10M–$105M
Investment Focus
Industry
- Biotechnology 18 (51%)
- Health Care 13 (37%)
- Medical 8 (23%)
- Therapeutics 8 (23%)
- Pharmaceutical 7 (20%)
Stage
- Series A 10 (29%)
- Series B 9 (26%)
- Funding Round 5 (14%)
- Series C 3 (9%)
- Venture - Series Unknown 3 (9%)
Country
- Canada 10 (29%)
- United States 8 (23%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Damian Lamb
Co-Founder and Managing Director
|
Co-Founder and Managing Director | Total investments: 1 | Find email | |
|
Jamie Stiff
Managing Director
|
Managing Director | Total investments: 8 | Find email | |
Jennifer Williams
Partner and CFO; Director of Finance and Operations
|
Partner and CFO; Director of Finance and Operations | Total investments: 0 | Find email | |
Kelly Holman
Co-Founder and Managing Director
|
Co-Founder and Managing Director | Total investments: 0 | Find email | |
Maxime Ranger
Venture Partner
|
Venture Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Enspire DBS Therapy supports stroke recovery patients using deep brain stimulation with physical rehabilitation to restore motor function. Enspire DBS offers a robust method to mediate the effects of stimulation and stroke rehabilitation. | $10.3M / Series B / Jan 13, 2026 | ||
| Feldan Therapeutics has developed a patented peptide-based technology platform, the Feldan Shuttle, which enables fast and safe intracellular delivery. The company's mission is to develop leading-edge therapeutic applications based on its proprietary platform, as demonstrated by its current pipeline of clinical programs taking advantage of theunique characteristics of the Shuttle. | $21M / Series B / Sep 04, 2024 | ||
| Flosonics is a medical device company that focuses on developing non-invasive sensors to improve the management of critically ill patients. Flosonics's flagship smart-bandage product, the FloPatch, addresses unmet clinical needs of critically ill patients and the physicians, nurses, and paramedics who care for them in the ambulance,emergency department, operating room, and intensive care unit. | $20M / Series C / Mar 19, 2024 | ||
| Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients. | $24M / Jun 20, 2023 | ||
| Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected bymetabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. | $69.3M / Series C / Oct 17, 2022 | ||
| Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients. | $16.6M / Series A / Jun 16, 2021 | ||
| Giiant is a preclinical-stage biotech company that, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerabilityand enhanced therapeutic effect. | $12.4M / Seed / May 21, 2021 | ||
| Flosonics is a medical device company that focuses on developing non-invasive sensors to improve the management of critically ill patients. Flosonics's flagship smart-bandage product, the FloPatch, addresses unmet clinical needs of critically ill patients and the physicians, nurses, and paramedics who care for them in the ambulance,emergency department, operating room, and intensive care unit. | $14M / Venture - Series Unknown / Feb 02, 2021 | ||
| Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected bymetabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. | $35M / Series B / Sep 08, 2020 | ||
| We passionately believe that infectious disease patients should be treated with the same precision that cancer patients receive today. As our population increases, our economies become more global, and we continue over-usage of broad-spectrum antibiotics, infectious diseases are going to continue to spread and become more pernicious. Our clinicalpractices must evolve with disease to become more precise in our diagnostic and treatment tools. At IDbyDNA, our goal is to accelerate these solutions and uncover the microbial world to reduce infectious disease-associated morbidity and mortality | $20M / Series B / Jan 29, 2020 | ||
| See all 35 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Genesys Capital invest in?
Genesys Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 35 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Genesys Capital's check size?
Genesys Capital typically joins rounds of $1.8M–$21M at Series A and $10M–$105M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Genesys Capital participates in.
How do I contact Genesys Capital?
Public channels for Genesys Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Genesys Capital?
The team at Genesys Capital includes Damian Lamb (Co-Founder and Managing Director), Jamie Stiff (Managing Director) and Jennifer Williams (Partner and CFO; Director of Finance and Operations). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
